NEW
YORK, Sept. 27, 2023 /PRNewswire/ -- Delcath
Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an
interventional oncology company focused on the treatment of primary
and metastatic cancers of the liver, announces that the Company
granted equity awards, in the form of a total of 86,000 shares of
the Company's common stock, outside of the Company's Omnibus 2020
Equity Incentive Plan as amended ("Plan"), previously approved by
the Company's Compensation Committee and the Board of Directors, as
a material inducement to employment of four new hires.
Delcath issued Ashleigh Lamson
20,0000 shares, Jessica Stevenson
20,000 shares, Andrea Prescod 18,500
shares, and Akash Patel 27,500
shares.
The Company issued options to each of the employees upon the new
employee's grant date, and all stock options included within the
equity inducement awards have an exercise price equal to the
closing price of Delcath common stock on the grant date of the
award and each award has a ten-year term. For each of the
awards, one-third of the options will vest on the first anniversary
of the grant date with the remaining two-thirds of the options
vesting in equal monthly installments over the following
twenty-four months.
The above-described awards were each granted in accordance with
NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the
terms of the Plan.
About Delcath Systems,
Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The Company's proprietary products, HEPZATO KIT™ (melphalan for
Injection/Hepatic Delivery System), approved for use in
the United States by the Food and
Drug Administration, and CHEMOSAT Hepatic Delivery System for
Melphalan percutaneous hepatic perfusion (PHP), designated under
the medical device regulation for use in Europe and the United Kingdom, are designed to administer
high-dose chemotherapy to the liver while controlling systemic
exposure and associated side effects during a PHP procedure. For
more information regarding HEPZATO KIT and its use, including
Important Safety Information and Boxed Warning, please visit
HEPZATOKIT.com. For more information regarding CHEMOSAT and
its use, please visit Chemosat.com.
Contact:
Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/delcath-systems-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301940936.html
SOURCE Delcath Systems, Inc.